Dr. S. Kondal Reddy, Dr. P. Srujan


Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by excess accumulation of fat in the liver
occurring in people who consume little or no alcohol. The amount of excess fat deposited in the liver in this
condition usually exceeds 5-10% by weight and is recognized by accumulation of triglyceride within the cytoplasm.
Aims & Objectives To estimate the prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetic patients and to study its
correlation with coronary artery disease and coronary risk factors. To study the correlation between fatty liver and coronary artery disease in
Methods This was a cross-sectional study conducted in Osmania General Hospital, Hyderabad. A Total of 150 patients above the age group
of 30yrs who were already diagnosed of type 2 diabetes mellitus and on treatment for T2 DM were recruited from Osmania Medical College
and hospital for the present study.
Results A total of 150 cases, it was observed that 54% of the diabetic patients had fatty liver and 46% had no fatty liver disease.
Conclusion The prevalence of NAFLD in type 2 diabetics is high, NAFLD is associated with metabolic syndrome, Coronary Artery Disease. In
NAFLD other components of metabolic syndrome like HTN, dyslipidemia should be looked for.


Non Alcoholic Fatty Liver Disease, Correlation with Coronary Artery Disease, Type 2 DM

Full Text:



Chalasani N, Younossi Z, lavine JE, Diehl AM, Brunt EM, Cusi K et al. the Diagnosis and Management of Non Alcoholic Fatty Liver Disease: the American Gastroenterologcial Association, hepatology 2012; 55 : 2005-23.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton LD, Cohen JC et al. prevalence of hepatic steatosis in an urban population in the United States; impact of ethnicity. Hepatology. 2004; 40:1387-95.

(Madan K, Batra Y, Panda SK, Dattagupta S, Hazari S, jha JK et al. Role of polymerase chain reaction and liver biopsy in the evaluation of patients with asymptomatic transaminitis: implications in diagnostic approach. J Gastroenterol Hepatol. 2004; 19:1291-9.

Ong JP,Pittis A, younossi ZM. Increased overall mortality and liver related mortality in non alcoholic fatty liver disease. J Hepatol. 2008; 49:608-12.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton LD, Cohen JC et al. prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 1387-95.

Agarwal AK, jain V, Singla S, baruah BP, Arya V, Yadav R et al. prevalence of non alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J. Assoc Physicians India 2011; 59:351-4).

Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L et al. Prevalence of non alcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30:1212-8.

Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, joshi SR et al prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc physicians India. 2009; 57:205-10.

Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non alcoholic fatty liver disease in older people. Gerontology. 2009; 55:607-13

Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease Gastroenterology. 2002; 122:1649-57.


  • There are currently no refbacks.